Another important drug target in melanoma is the deubiquitinase USP9X (X-linked ubiquitin-specific peptidase 9), which prevents the degradation of ubiquitin-specific proteins that are essential in various biological pathways involved in the regulation of cell transformation and survival. Here, USP9X is linked to melanoma.